Cephalon Inc. - CEPH- Profile

Cephalon, Inc.. The Group's principal activity is to discover, develop and market products to treat neurological disorders and cancers. The Group researches to develop suitable drugs in treatment of neurological disorders like ALS, narcolepsy, peripheral neuropathies, head and spinal injury, Alzheimer's and stroke. Its products are Provigil(R), ACTIQ (R), NUVIGIL and GABITRIL (R). Provigil tablets are used by those suffering from excessive daytime sleepiness associated with narcolepsy; ACTIQ (R), for the management of breakthrough cancer pain in opioid tolerant patients and the further development of Gabitril (R), an adjunctive treatment for partial seizures associated with epilepsy. The Group operates in the United States, France, the United Kingdom, Germany, Italy, the Netherlands and Switzerland. United States accounted for 83% of 2006 revenues and Europe, 17%